# Study Comparing Two VAY736 Drug Products in Patients With Rheumatoid Arthritis

> **NCT03574545** · PHASE1 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 48 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **BIOLOGICAL:** ianalumab

## Key facts

- **NCT ID:** NCT03574545
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-12-19
- **Primary completion:** 2024-07-18
- **Final completion:** 2024-07-18
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2025-12-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03574545

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03574545, "Study Comparing Two VAY736 Drug Products in Patients With Rheumatoid Arthritis". Retrieved via MORVS 2026-10-12 from https://api.morvs.ai/clinical/NCT03574545. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*